ArticleBMC surgery2026
Radiomics-based prediction model for lymph node metastasis in thyroid microcarcinoma.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop and validate a predictive model for lymph node metastasis (LNM) in thyroid microcarcinoma (TMC) based on clinical, ultrasonographic, and radiomic features, providing a basis for accurate preoperative risk assessment and individualized surgical planning.
methodsA total of 426 TMC patients treated at our institution from June 2022 to December 2024 were retrospectively enrolled and randomly divided into a training set (n = 300) and a validation set (n = 126) at a 7:3 ratio. Demographic characteristics (age, gender), preoperative clinical and ultrasonographic features (tumor size measured by ultrasound, multifocality assessed by ultrasound, capsular invasion on ultrasound, etc.), ultrasound features (lymph node size, sphericity, etc.), laboratory indicators (preoperative TSH level), and radiomic parameters (3D tumor volume, surface area, etc.) were collected. In the training set, univariate analysis was performed to screen LNM-associated factors, followed by LASSO regression for variable selection. Multivariate logistic regression was used to identify independent predictors. Random forest (RF), K-nearest neighbors (KNN), and gradient boosting (GB) models were constructed. The model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA) in the training and internal validation sets.
resultsNo significant differences in baseline characteristics were observed between the training and validation sets (P > 0.05). Univariate analysis revealed that tumor size, lymph node size, TSH level, central lymph node metastasis, 3D tumor volume, and sphericity were associated with LNM (P < 0.05). Multivariate logistic regression identified tumor size, lymph node size, TSH level, central lymph node metastasis, and 3D tumor volume as independent risk factors for LNM (P < 0.05), while sphericity was an independent protective factor (P < 0.05). The RF model exhibited superior performance (training AUC: 0.838, internal validation AUC: 0.815) compared to KNN (0.815, 0.792) and GB (0.787, 0.763), demonstrating good calibration and stable clinical net benefit.
conclusionThe RF model constructed using multidimensional features effectively predicts LNM in TMC, with TSH level, tumor size, and sphericity as key predictors, demonstrating high clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.